AIMS/HYPOTHESIS: Individuals with heterozygous activating mutations of the KCNJ11 gene encoding a subunit of the ATP-sensitive potassium channel (KATP) can usually be treated with oral sulfonylurea (SU) pills in lieu of insulin injections. The aim of this study was to test our hypothesis that younger age at the time of initiation of SU therapy is correlated with lower required doses of SU therapy, shorter transition time and decreased likelihood of requiring additional diabetes medications. METHODS: We performed a retrospective cohort study using data on 58 individuals with neonatal diabetes due to KCNJ11 mutations identified through the University of Chicago Monogenic Diabetes Registry ( http://monogenicdiabetes.uchicago.edu/registry ). We assessed the influence of age at initiation of SU therapy on treatment outcomes. RESULTS: HbA1c fell from an average of 8.5% (69 mmol/mol) before transition to 6.2% (44 mmol/mol) after SU therapy (p < 0.001). Age of initiation of SU correlated with the dose (mg kg(-1) day(-1)) of SU required at follow-up (r = 0.80, p < 0.001). Similar associations were observed across mutation subtypes. Ten participants required additional glucose-lowering medications and all had initiated SU at age 13 years or older. No serious adverse events were reported. CONCLUSIONS/ INTERPRETATION: Earlier age at initiation of SU treatment is associated with improved response to SU therapy. Declining sensitivity to SU may be due to loss of beta cell mass over time in those treated with insulin. Our data support the need for early genetic diagnosis and appropriate personalised treatment in all cases of neonatal diabetes.
AIMS/HYPOTHESIS: Individuals with heterozygous activating mutations of the KCNJ11 gene encoding a subunit of the ATP-sensitive potassium channel (KATP) can usually be treated with oral sulfonylurea (SU) pills in lieu of insulin injections. The aim of this study was to test our hypothesis that younger age at the time of initiation of SU therapy is correlated with lower required doses of SU therapy, shorter transition time and decreased likelihood of requiring additional diabetes medications. METHODS: We performed a retrospective cohort study using data on 58 individuals with neonatal diabetes due to KCNJ11 mutations identified through the University of Chicago Monogenic Diabetes Registry ( http://monogenicdiabetes.uchicago.edu/registry ). We assessed the influence of age at initiation of SU therapy on treatment outcomes. RESULTS: HbA1c fell from an average of 8.5% (69 mmol/mol) before transition to 6.2% (44 mmol/mol) after SU therapy (p < 0.001). Age of initiation of SU correlated with the dose (mg kg(-1) day(-1)) of SU required at follow-up (r = 0.80, p < 0.001). Similar associations were observed across mutation subtypes. Ten participants required additional glucose-lowering medications and all had initiated SU at age 13 years or older. No serious adverse events were reported. CONCLUSIONS/ INTERPRETATION: Earlier age at initiation of SU treatment is associated with improved response to SU therapy. Declining sensitivity to SU may be due to loss of beta cell mass over time in those treated with insulin. Our data support the need for early genetic diagnosis and appropriate personalised treatment in all cases of neonatal diabetes.
Authors: Ricard Masia; Joseph C Koster; Stefano Tumini; Francesco Chiarelli; Carlo Colombo; Colin G Nichols; Fabrizio Barbetti Journal: Diabetes Date: 2007-02 Impact factor: 9.461
Authors: Siri Atma W Greeley; Rochelle N Naylor; Lindsay S Cook; Susan E Tucker; Rebecca B Lipton; Louis H Philipson Journal: J Diabetes Sci Technol Date: 2011-07-01
Authors: D Iafusco; C Bizzarri; F Cadario; R Pesavento; G Tonini; S Tumini; V Cauvin; C Colombo; R Bonfanti; F Barbetti Journal: Diabetologia Date: 2011-08-07 Impact factor: 10.122
Authors: Brigid E Gregg; Patrick C Moore; Damien Demozay; Ben A Hall; Mei Li; Aliya Husain; Amy J Wright; Mark A Atkinson; Christopher J Rhodes Journal: J Clin Endocrinol Metab Date: 2012-06-28 Impact factor: 5.958
Authors: Tomasz Klupa; Jan Skupien; Barbara Mirkiewicz-Sieradzka; Agnieszka Gach; Anna Noczynska; Agnieszka Zubkiewicz-Kucharska; Mieczyslaw Szalecki; Elzbieta Kozek; Joanna Nazim; Wojciech Mlynarski; Maciej T Malecki Journal: Diabetes Technol Ther Date: 2010-05 Impact factor: 6.118
Authors: Julie Støy; Siri Atma W Greeley; Veronica P Paz; Honggang Ye; Ashley N Pastore; Kinga B Skowron; Rebecca B Lipton; Fran R Cogen; Graeme I Bell; Louis H Philipson Journal: Pediatr Diabetes Date: 2008-07-25 Impact factor: 4.866
Authors: Sarah E Flanagan; Séverine Clauin; Christine Bellanné-Chantelot; Pascale de Lonlay; Lorna W Harries; Anna L Gloyn; Sian Ellard Journal: Hum Mutat Date: 2009-02 Impact factor: 4.878
Authors: Thais Della Manna; Claudilene Battistim; Vanessa Radonsky; Roberta D Savoldelli; Durval Damiani; Fernando Kok; Ewan R Pearson; Sian Ellard; Andrew T Hattersley; André F Reis Journal: Arq Bras Endocrinol Metabol Date: 2008-11
Authors: Monica S Lanning; David Carmody; Łukasz Szczerbiński; Lisa R Letourneau; Rochelle N Naylor; Siri Atma W Greeley Journal: Pediatr Diabetes Date: 2017-12-05 Impact factor: 4.866
Authors: Karen A Landmeier; Monica Lanning; David Carmody; Siri Atma W Greeley; Michael E Msall Journal: Pediatr Diabetes Date: 2016-08-24 Impact factor: 4.866